Here are the presentations from the VicTAG Education Webinar held after the Annual General Meeting 2023:
Check Again: Improving antibiotic treatment options for patients with penicillin allergy - Misha Devchand, Safer Care Victoria
Improving childhood asthma management inner west pilot project a- Rachel Vorlander, Safer Care Victoria
VicTAG framework for the implementation and integration of automated dispensing cabinets - Viviane Khalil, Monash Health
VicTAG framework for the management of Schedule 9, Schedule 8 and Schedule 4D medications - Cynthia Donarelli, Northern Health
Medication safety assessment of pharmaceutical products - Rowena Treseder, Alfred Health
VicTAG medication safety alerts and 2023 highlights - Connie Yin, VicTAG
Thank you to all our presenters at the event.
The VicTAG QUM Committee Terms of Reference is available here:
The Medicines and Poisons Regulation opened a public consultation in relation to the proposed amendment to include pregabalin, gabapentin and tramadol in SafeScript.
The Regulatory Impact Statement (RIS) in relation to the proposed Drugs, Poisons and Controlled Substances Amendment Regulations 2023 (proposed Regulations) has been prepared in accordance with section 11 of the Subordinate Legislation Act 1994. The RIS presents the cost to prescribers and pharmacists implementing the proposed Regulations and the expected health, social and financial benefits.
The RIS draws on the findings of the Austin Health updated literature review with regards to the evidence of harms caused by pregabalin, gabapentin and tramadol. You can find the full report here - https://www.health.vic.gov.au/drugs-and-poisons/medicines-monitored-in-safescript.
Links below to consultation documents and the response submitted by VicTAG
Regulatory Impact Statement - Schedule 5 & Schedule 6 of the DPCS Regulations 2017
Exposure draft - DPCS Amendment Regulations 2023
VicTAG Response to proposed amendement
You must be a member and be signed in to view this page. Please click here to login if you are already a member.
strategies to deal with the lack of development into agents targeting microbial infections was held. The current business model for drug development does not work with antimicrobials and consequently almost all large pharma are no long involved in drug development in this space.
The meeting was to discuss different options with various players and the slides are available below.
Download